OATP1B3 IC50 Determination – Transfected Cells

This assay is used to determine the IC50 of a test compound for inhibition of OATP1B3 in OATP1B3-transfected HEK293 cells.

Required from Customer
  • Either a minimum of 300 µL of test compound at 20 mM in DMSO, or 10 mg of powder
  • Exact molecular mass of test compound and its salt form
  • Relevant solubility of the test compound
  • MSDS or handling and storage information, e.g., light sensitive, store at -20°C, etc.


  • Normalized uptake of atorvastatin in the presence and absence of test compound in OATP1B3-transfected and vector control cells
  • IC50 of the test compound


  • OATP1B3 probe substrate atorvastatin at 0.15 μM
  • Test compound at six concentrations (serial diluations from 100 µM) in modified Hanks’ buffer with less than 0.8% DMSO

Assay System

  • OATP1B3-transfected HEK293 cells and vector control cells cultured in 24-well plates

Assay Conditions

  • Measure uptake of atorvastatin in OATP1B3-transfected and vector control cells with and without test compound
  • Six concentrations of test compound
    • Single incubation (n=1) per concentration
  • Negative control: vehicle only
    • Duplicate incubations (n=2)
  • Positive control: single concentration of known inhibitor rifamycin SV
    • Duplicate incubations (n=2)
  • Two cell lines: OATP1B3-transfected and vector control cell lines
  • Treatments performed in each cell line:
    • Wells are equilibrated with blank buffer containing 1% BSA prior to initiating the assay
    • Buffer is aspirated and replaced with dosing solution
    • Incubate cells for 5 min at 37°C
    • Terminate the incubation and lyse the cells
    • Analyze cell lysate using LC-MS/MS to determine atorvastatin concentration
    • Determine protein concentration in cell lysate and normalize atorvastatin concentration to protein content

Assay QC

  • Uptake rate of probe substrate in OATP1B3-transfected vs. vector control cells
  • Inhibition of probe substrate uptake by a known inhibitor of OATP1B3


  1. The results from this assay are provided to the customer in the ExpressPlus report format, which may include graphical representations of data and comparison with historical data for reference compounds.
  2. The solubility of the test compound in Hanks’ buffer containing < 0.8% DMSO must be greater than the test concentration. If the solubility of the test compound is unavailable, Absorption Systems can conduct a solubility assessment at an additional charge.